Market revenue in 2021 | USD 20.6 million |
Market revenue in 2030 | USD 169.4 million |
Growth rate | 26.4% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 33.01% in 2021. Horizon Databook has segmented the China non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
The histological characteristic that accurately predicts the severity and prognosis of NASH is fibrosis. Research funded by the Jiangsu Province's Natural Science Foundation investigated novel genes associated with the development of fibrosis in NASH.
The study discovered novel genes linked to NASH fibrosis and examined how they affected fibrosis from a single-cell viewpoint. These findings could lead to new approaches for the early detection, supervision, assessment, and forecasting of fibrosis progression in NASH.
Key players are engaged in the R&D of NASH treatment and biomarkers for diagnosing disease progression. In March 2021, Ascletis Pharma, Inc. and Sagimet Biosciences, Inc. codeveloped once-daily fatty acid synthase inhibitor ASC40 and completed the phase 2 clinical trial with positive results for the treatment of NASH.
Horizon Databook provides a detailed overview of country-level data and insights on the China non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into China non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account